S516
Clinical - Haemotology
ESTRO 2026
involvement. Radiotherapy techniques included 3D conformal (79%), VMAT (14%), IMRT (5%), and electron therapy (3%). Prescribed doses ranged from 4.0 to 37.8 Gy (median 24 Gy); 98% received ≤ 30 Gy. Radiotherapy was delivered as first - line treatment in 52% and following chemotherapy in 48%. Follow - up was calculated from start of radiotherapy. Primary endpoints were local control (LC), progression - free survival (PFS), overall survival (OS), and treatment - related toxicity. Survival estimates were obtained by Kaplan–Meier analysis and subgroup comparisons by log - rank test. Results: Median follow-up was 42 months (range 9–134). Five- year local control (LC), progression-free survival (PFS), and overall survival (OS) rates were 96%, 76%, and 85%, respectively. Five-year OS was 79% for follicular lymphoma (FL) and 97% for marginal zone lymphoma (MZL) (p = 0.061). Five-year PFS was 74% for FL and 87% for MZL (p = 0.126). For nodal disease, five-year OS and PFS in patients treated solely with radiotherapy were 93% and 77%, respectively, compared to 81% and 67% in patients receiving chemotherapy. For extranodal disease, five-year OS and PFS were 85% and 85% in the radiotherapy-only group versus 82% and 71% in the chemotherapy group (OS p = 0.311; PFS p = 0.309). By stage, five-year OS and PFS were 91% and 85% for stage I–II, versus 77% and 68% for stage III–IV (OS p = 0.057; PFS p = 0.040). Adverse effects were uncommon and mild, limited to grade 1 in 10% of patients. Conclusion: Radiotherapy is a highly effective and well-tolerated treatment for iNHL, particularly in patients with MZL, nodal involvement, and early-stage disease. These results support its continued use as a safe and beneficial therapeutic option. References: Elsayad K, Reinartz G, Oertel M, et al. Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients. Strahlenther Onkol. 2020;196(2):117-125. doi:10.1007/s00066-019-01538-2Hadi I, Schummer A, Dreyling M, et al. Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin's
knowledge between centers may support the optimization of long-term outcomes by reducing dose- related complications in organs of interest. References: [1] Starke A, Bowden J, Lynn R, et al. Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma. Radiother Oncol. 2018 Dec;129(3):449-455.[2] Aznar MC, Maraldo MV, Schut DA, et al. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both? IJROBP. 2015 May 1;92(1):169-74.[3] Mohanty S, Patil D, Joshi K, et al. Dosimetric Impact of Voluntary Deep Inspiration Breath Hold in Mediastinal Hodgkin Lymphomas: A Comparative Evaluation of Three Different IMRT Delivery Methods Using Voluntary DIBH and Free Breathing Techniques. Cancers. 2024 Feb 6;16(4):690. Keywords: Breath Hold, Mediastinal Lymphoma, Survey Digital Poster 3326 Outcomes and Tolerability of Radiotherapy in Patients with Indolent Non-Hodgkin Lymphoma: A Retrospective Analysis from a Single Institution Lea Galunic Bilic 1 , Sandra Basic Kinda 2 , Barbara Dreta 2 , Ida Hude Dragicevic 2 , Dino Dujmovic 2 , Margareta Dobrenic 3 , Ivana Ilic 4,5 , Ruzica Galunic Cicak 6 , Majda Turalija 1 , Borna Arsov 1 , Igor Aurer 2,7 1 Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia. 2 Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia. 3 Department of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb, Zagreb, Croatia. 4 Department of Pathology, University Hospital Centre Zagreb, Zagreb, Croatia. 5 Department of Pathology, School of Medicine University of Zagrebva, Zagreb, Croatia. 6 Department of Radiology, University Hospital Centre Zagreb, Zagreb, Croatia. 7 Department of Hematology, School of Medicine University of Zagrebva, Zagreb, Croatia Purpose/Objective: To assess the clinical outcomes and tolerability of radiotherapy in patients with indolent non-Hodgkin lymphoma (iNHL) treated at our institution over a ten- year period. Material/Methods: We retrospectively reviewed records of 122 patients with histologically confirmed iNHL treated with radiotherapy at our institution between 2014 and 2024. The cohort comprised follicular lymphoma (FL, n = 84) and marginal zone lymphoma (MZL, n = 38). At diagnosis, 72 patients (59%) had stage I–II disease and 50 (41%) had stage III–IV; 54% had extranodal
lymphoma: a monocenter analysis. Sci Rep. 2021;11(1):22586. Published 2021 Nov 19.
doi:10.1038/s41598-021-01851-wHoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457-463. doi:10.1016/S1470- 2045(14)70036-1 Keywords: Indolent Non-Hodgkin's lymphoma, Radiotherapy
Made with FlippingBook - Share PDF online